Arginine-rich cell penetrating peptides: Design, structure-activity, and applications to alter pre-mRNA splicing by steric-block oligonucleotides

Journal of Peptide Science

Volumn 14, Issue 4, 2008, Pages 455-460

  Abes, R ^a   Arzumanov, A ^b   Moulton, H ^c   Abes, S ^a   Ivanova, G ^b   Gait, M J ^b   Iversen, P ^c   Lebleu, B ^a  

^a UNIVERSITÉ DE MONTPELLIER   (France)

^b MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^c AVI BIOPHARMA INC   (United States)

Author keywords

Cell penetrating peptides; Delivery; Splicing correction; Steric block oligonucleotldes

Indexed keywords

AMINOCAPROIC ACID; ANTISENSE OLIGONUCLEOTIDE; ARGININE RICH PEPTIDE AMINOHEXANOIC ACID ARGININE TAILED PENETRATIN PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER CONJUGATE; BETA GLOBIN; CELL PENETRATING PEPTIDE; LIPOSOME; MESSENGER RNA PRECURSOR; NANOPARTICLE; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG;

DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG MECHANISM; GENE CONTROL; GENE MUTATION; GENE TARGETING; HUMAN; INTERNALIZATION; MUSCULAR DYSTROPHY; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REVIEW; RNA SPLICING; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION; TRANSLATION INITIATION;

ANIMALS; ARGININE; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; HUMANS; OLIGONUCLEOTIDES; PEPTIDES; RNA PRECURSORS; RNA SPLICING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 42149194279     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.979     Document Type: Review

References (38)

1. Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. 2003; 270: 1628-1644.
2. Scanlon KJ. Anti-genes: siRNA, ribozymes and antisense. Curr. Pharm. Biotechnol. 2004; 5: 415-420.
3. Crooke ST. Progress in antisense technology. Annu. Rev. Med. 2004; 55: 61-95.
4. Que-Gewirth NS, Sullenger BA. Gene therapy progress and prospects: RNA aptamers. Gene Ther. 2007; 14: 283-291.
5. Abes S, Moulton HM, Clair P, Prevot P, Youngblood DS, Wu RP, Iversen PL, Lebleu B. Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents. J. Control. Release 2006; 116: 304-313.
6. Abes S, Turner JJ, Ivanova GD, Owen D, Williams D, Arzumanov A, Clair P, Gait MJ, Lebleu B. Efficient splicing correction by PNA conjugation to an R6-Penetratin delivery peptide. Nucleic Acids Res. 2007; 35: 1-8.
7. Fletcher S, Honeyman K, Fall AM, Harding PL, Johnsen RD, Steinhaus JP, Moulton HMH, Iversen PL, Wilton SD. Morpholino oligomer mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Mol. Ther. 2007; 151: 587-592.
8. Kole R, Williams T, Cohen L. RNA modulation, repair and remodeling by splice switching oligonucleotides. Acta Biochim. Pol. 2004; 51: 373-378.
9. Venables JP. Aberrant and alternative splicing in cancer. Cancer Res. 2004; 64: 7647-7654.
10. Garcia-Blanco MA, Baraniak AP, Lasda EL. Alternative splicing in disease and therapy. Nat. Biotechnol. 2004; 22: 535-546.
11. Hogrefe RI. An antisense oligonucleotide primer. Antisense Nucleic Acid Drug Dev. 1999; 9: 351-357.
12. Thierry AR, Vives E, Richard JP, Prevot P, Martinand-Mari C, Robbins I, Lebleu B. Cellular uptake and intracellular fate of antisense oligonucleotides. Curr. Opin. Mol. Ther. 2003; 5: 133-138.
13. Debart F, Abes S, Deglane G, Moulton HM, Clair P, Gait MJ, Vasseur JJ, Lebleu B. Chemical modifications to improve the cellular uptake of oligonucleotides. Curr. Top. Med. Chem. 2007; 7: 727-737.
14. Bergan R, Hakim F, Schwartz GN, Kyle E, Cepada R, Szabo JM, Fowler D, Gress R, Neckers L. Electroporation of synthetic oligodeoxynucleotides: a novel technique for ex vivo bone marrow purging. Blood 1996; 88: 731-741.
15. Resina S, Kole R, Travo A. Lebleu B, Thierry AR. Switching on transgene expression by correcting aberrant splicing using multi-targeting steric-blocking oligonucleotides. J. Gene Med. 2007; 9: 498-510.
16. Torchilin VP. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu. Rev. Biomed. Eng. 2006; 8: 343-375.
17. Leonetti JP, Degols G, Lebleu B. Biological activity of oligonucleotide-poly(L-lysine) conjugates: mechanism of cell uptake. Bioconjug. Chem. 1990; 1: 149-153.
18. Leonetti JP, Rayner B, Lemaitre M, Gagnor C, Milhaud PG, Imbach JL, Lebleu B. Antiviral activity of conjugates between poly(L-lysine) and synthetic oligodeoxyribonucleotides. Gene 1988; 72: 323-332.
19. Dietz GP, Bahr M. Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol. Cell. Neurosci. 2004; 27: 85-131.
20. Vives E, Granier C, Prevot P, Lebleu B. Structure activity relationship study of the plasma membrane translocating potential of a short peptide from HIV-1 Tat protein. Lett. Pept. Sci. 1997; 4: 429-436.
21. Abes S, Richard JP, Thierry AR, Clair P, Lebleu B. Tat-derived cell-penetrating peptides: discovery, mechanism of cell uptake, and applications to the delivery of oligonucleotides. Handbook of Cell-Penetrating Peptides, 2nd edn, CRC Press: Boca Raton, 2007; 29-42.
22. Derossi D, Joliot AH, Chassaing G, Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 1994; 269: 10444-10450.
23. Derossi D, Chassaing G, Prochiantz A. Trojan peptides: the penetratin system for intracellular delivery. Trends Cell. Biol. 1998: 8: 84-87.
24. Patel LN, Zaro JL, Shen WC. Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives. Pharm. Res. 2007; 24(11): 1977-1992.
25. Fischer R, Fotin-Mleczek M. Hufnagel H, Brock R. Break on through to the other side-biophysics and cell biology shed light on cell-penetrating peptides. Chembiochem 2005: 6: 2126-2142.
26. Richard JP, Melikov K, Vives E, Ramos C, Verbeure B, Gait MJ, Chernomordik LV, Lebleu B. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J. Biol. Chem. 2003; 278: 585-590.
27. Wadia. JS, Stan RV, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. 2004; 10: 310-315.
28. Abes S, Williams D, Prevot P, Thierry A, Gait MJ, Lebleu B. Endosome trapping limits the efficiency of splicing correction by PNA-oligolysine conjugates. J. Control. Release 2006; 110: 595-604.
29. Abes Moulton H, Turner J, Clair P, Richard JP, Iversen P, Gait MJ, Lebleu B. Peptide-based delivery of nucleic acids: design, mechanism of uptake and applications to splice-correcting oligonucleotides. Biochem. Soc. Trans. 2007; 35: 53-55.
30. Kilk K, Elmquist A, Saar K, Pooga M, Land T, Bartfai T, Soomets U, Langel U. Targeting of antisense PNA oligomers to human galanin receptor type 1 mRNA. Neuropeptides 2004; 38: 316-324.
31. Kang SH, Cho MJ, Kole R. Up-regulation of luciferase gene expression with antisense oligonucleotides: implications and applications in functional assay development. Biochemistry 1998; 37: 6235-6239.
32. Turner JJ, Ivanova GD, Verbeure B, Williams D, Arzumanov AA, Abes S, Lebleu B, Gait MJ. Cell-penetrating peptide conjugates of peptide nucleic acids (PNA) as inhibitors of HIV-1 Tat-dependent trans-activation in cells. Nucleic Acids Res. 2005; 33: 6837-6849.
33. Shiraishi T, Nielsen PE. Enhanced delivery of cell-penetrating peptide-peptide nucleic acid conjugates by endosomal disruption. Nat. Protoc. 2006; 1: 633-636.
34. Abes S, Turner JJ, Ivanova GD, Owen D, Williams D, Arzumanov A, Clair P, Gait MJ, Lebleu B. Efficient splicing correction by PNA conjugation to an R6-Penetratin delivery peptide. Nucleic Acids Res. 2007; 35: 1-8.
35. Rothbard JB, Kreider E, VanDeusen CL, Wright L, Wylie BL, Wender PA. Arginine-rich molecular transporters for drug delivery: role of backbone spacing in cellular uptake. J. Med. Chem. 2002; 45: 3612-3618.
36. Abes R, Arzumanov AA, Moulton H, Abes S, Ivanova GD, Iversen PL, Gait MJ, Lebleu B. Cell penetrating peptide-based delivery of oligonucleotides: an overview. Biochem. Soc. Trans. (in press).
37. Fletcher S, Honeyman K, Fall AM, Harding PL, Johnsen RD, Steinhaus JP, Moulton HM, Iversen PL, Wilton SD. Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Mol. Ther. 2007; 15(9): 1587-1592.
38. Abes S, Moulton HM, Clair P, Prevot P, Youngblood DS, Wu RP, Iversen PL, Lebleu B. Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents. J. Control. Release. 2006; 116: 304-313.